|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent AGLE insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why AGLE insider buys are important for investors to follow.
Date | Insider | Price | Amount |
8-25-2022 Insider Buy |
Marcio Souza Director |
$0.56
CAGR »
|
$50,472.00 90,000 shares |
3-16-2022 Insider Buy |
Anthony G. Quinn President & CEO |
$2.34
CAGR »
|
$187,705.18 80,079 shares |
3-11-2022 Insider Buy |
Jonathan Alspaugh Chief Financial Officer |
$2.08
CAGR »
|
$156,000.00 75,000 shares |
3-15-2022 Insider Buy |
Anthony G. Quinn President & CEO |
$1.94
CAGR »
|
$280,942.97 144,666 shares |
12-9-2021 Insider Buy |
Jonathan Alspaugh Chief Financial Officer |
$3.72
CAGR »
|
$186,000.00 50,000 shares |
12-10-2021 Insider Buy |
Anthony G. Quinn President & CEO |
$3.71
CAGR »
|
$198,972.10 53,634 shares |
12-13-2021 Insider Buy |
Armen Shanafelt Director |
$3.66
CAGR »
|
$549,692.38 150,000 shares |
8-18-2021 Insider Buy |
Jonathan Alspaugh Chief Financial Officer |
$6.51
CAGR »
|
$262,659.81 40,372 shares |
4-30-2020 Insider Buy |
Anthony G. Quinn President & CEO |
$4.75
CAGR »
|
$783,750.00 165,000 shares |
12-7-2018 Insider Buy |
Anthony G. Quinn President & CEO |
$7.05
CAGR »
|
$21,115.22 2,994 shares |
12-8-2017 Insider Buy |
Anthony G. Quinn Interim CEO |
$4.96
CAGR »
|
$41,078.38 8,288 shares |
12-5-2017 Insider Buy |
Anthony G. Quinn Director |
$4.86
CAGR »
|
$83,177.50 17,121 shares |
12-5-2017 Insider Buy |
Charles N. York II Chief Financial Officer and VP |
$4.48
CAGR »
|
$116,222.95 25,959 shares |
2-21-2017 Insider Buy |
ORBIMED ADVISORS LLC >10% Owner |
$5.16
CAGR »
|
$563,882.00 109,300 shares |
4-12-2016 Insider Buy |
Anthony Quinn Director |
$10.00
CAGR »
|
$100,000.00 10,000 shares |
4-12-2016 Insider Buy |
Russell J. Cox Director |
$10.00
CAGR »
|
$70,000.00 7,000 shares |
4-12-2016 Insider Buy |
Bioventures Ltd Novartis >10% Owner |
$10.00
CAGR »
|
$3,000,000.00 300,000 shares |
Also See: Institutional Holders of AGLE
Also See: SEC filings
Below we present the annualized performance delivered by AGLE stock since 8-25-2022 (the date of the most recent
insider purchase). The performance of the investment from the time AGLE insider buying occurred is the ultimate
test of whether insiders were right about AGLE being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/26/2022 |
|
End date: |
11/27/2023 |
|
Start price/share: |
$12.95 |
|
End price/share: |
$12.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-7.26% |
|
Average Annual Total Return: |
-5.83% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,273.97 |
|
Years: |
1.25 |
|
AGLE Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent AGLE insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding AGLE
|
|